Natalizumab treatment modulates Peroxisome Proliferator-Activated Receptors expression in women with multiple sclerosis

Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression i...

ver descrição completa

Detalhes bibliográficos
Autor principal: Ferret-Sena, Véronique (author)
Outros Autores: Silva, Alexandra Maia e (author), Sena, Armando (author), Cavaleiro, Inês (author), Vale, José (author), Derudas, Bruno (author), Chinetti-Gbaguidi, Giulia (author), Staels, Bart (author)
Formato: article
Idioma:eng
Publicado em: 2017
Assuntos:
Peroxisome Proliferator-Activated Receptors
Natalizumab
Multiple Sclerosis
Women
Texto completo:http://hdl.handle.net/10400.26/19449
País:Portugal
Oai:oai:comum.rcaap.pt:10400.26/19449

Texto Completo

http://hdl.handle.net/10400.26/19449

Registos relacionados